Stocksigma LogoStocksigma Logo

CARE Ratings Reaffirms Vimta Labs' Debt Facilities with a Stable Outlook

On 2nd Sep'26, CARE reaffirmed Vimta Labs' credit ratings at CARE A; Stable for long-term and CARE A1 for short-term bank facilities

CARE Ratings Reaffirms Vimta Labs' Debt Facilities with a Stable Outlook

Vimta Labs Ltd · Others (Uncategorized) · 03 Sept 2026, 12:36 am

CARE Ratings Reaffirms Vimta Labs' Debt Facilities with a Stable Outlook On 2nd Sep'26, CARE reaffirmed Vimta Labs' credit ratings at CARE A; Stable for long-term and CARE A1 for short-term bank facilities. The rating reflects Vimta's strong FY26 financial performance, driven by robust growth in pharmaceutical research. Total operating income reached ₹411.04 crore with impressive PBILDT and PAT margins of 35.26% and 18.86%, respectively. Vimta maintains a conservative capital structure with negligible 0.01x overall gearing and strong liquidity. Future growth is supported by a planned ₹60 crore FY27 capex targeting its upcoming Biologics segment commercialization.

Original exchange filing (PDF)

More announcements from Vimta Labs Ltd

All Vimta Labs Ltd announcements